Loading...
Alterity Therapeutics Limited
ATH.AX•ASX
Healthcare
Biotechnology
A$0.01
A$0.00(0.00%)
Alterity Therapeutics Limited (ATH.AX) Financial Performance & Income Statement Overview
Review Alterity Therapeutics Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
2.63%
↑ 2.63%
Operating Income Growth
-33.93%
↓ 33.93%
Net Income Growth
-38.51%
↓ 38.51%
Operating Cash Flow Growth
37.08%
↑ 37.08%
Operating Margin
-606.47%
↓ 606.47%
Gross Margin
96.32%
↑ 96.32%
Net Profit Margin
-531.34%
↓ 531.34%
ROE
-183.37%
↓ 183.37%
ROIC
-288.51%
↓ 288.51%
Alterity Therapeutics Limited (ATH.AX) Income Statement & Financial Overview
Review Alterity Therapeutics Limited's (ATH.AX) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $2.12M | $1.90M | $1.53M | $2.39M |
| Cost of Revenue | $73612.00 | $73917.00 | $52267.00 | $49996.00 |
| Gross Profit | $2.04M | $1.83M | $1.48M | $2.34M |
| Gross Profit Ratio | $0.97 | $0.96 | $0.97 | $0.98 |
| R&D Expenses | $12.28M | $6.36M | $5.43M | $7.76M |
| SG&A Expenses | $2.75M | $2.08M | $2.29M | $2.94M |
| Operating Expenses | $14.98M | $8.45M | $7.72M | $10.70M |
| Total Costs & Expenses | $15.10M | $8.52M | $7.77M | $10.75M |
| Interest Income | $150019.00 | $118400.00 | $5057.00 | $11379.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $73612.00 | $73917.00 | $52267.00 | $49996.00 |
| EBITDA | -$14.62M | -$8.33M | -$7.25M | -$10.26M |
| EBITDA Ratio | -$6.90 | -$4.44 | -$5.04 | -$4.48 |
| Operating Income | -$15.10M | -$8.52M | -$7.77M | -$10.75M |
| Operating Income Ratio | -$7.13 | -$4.48 | -$5.08 | -$4.51 |
| Other Income/Expenses (Net) | $412988.00 | $111345.00 | $470830.00 | $435955.00 |
| Income Before Tax | -$14.69M | -$8.41M | -$7.30M | -$10.31M |
| Income Before Tax Ratio | -$6.93 | -$4.42 | -$4.77 | -$4.32 |
| Income Tax Expense | -$2.07M | -$1.90M | -$1.53M | -$2.28M |
| Net Income | -$12.62M | -$6.51M | -$5.77M | -$8.03M |
| Net Income Ratio | -$5.96 | -$3.42 | -$3.77 | -$3.37 |
| EPS | -$0.002 | -$0.003 | -$0.002 | -$0.003 |
| Diluted EPS | -$0.002 | -$0.003 | -$0.002 | -$0.003 |
| Weighted Avg Shares Outstanding | $6.31B | $2.50B | $2.44B | $2.41B |
| Weighted Avg Shares Outstanding (Diluted) | $6.31B | $2.50B | $2.44B | $2.41B |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan